Latest From Biotech Now

Fuels America Sends a Valentine to the Oil Refiners

We Love Oil!

Fuels America (@FuelsAmerica) today sent an early Valentine card to the oil refining industry. Turns out, many Americans — who paid an extra $257 at the pump last year while using fewer gallons of gas — are in love with oil. On this (Hallmark) holiday, check out the Fuels America valentine video — We Love Oil! —  and share it with your loved ones or anyone who would be interested in learning the truth about our transportation Read More >

Biofuels & Climate Change  |  Leave a comment  |  Email This Post
Tags: , , , ,

Onyx CEO One of 25 Most Influential People in Biopharm Today According to FierceBiotech

Tony Coles

After a stellar year, as evidenced by inclusion in the second annual FierceBiotech “25 Most Influential People in Bipoharma Today,” N. Anthony (Tony) Coles, MD, Chairman & CEO of Onyx Pharmaceuticals sat down with Steve Usdin, Senior Editor of BioCentury for an early morning Fireside Chat at the 15th Annual BIO CEO & Investor Conference. To read more about Onyx’s stellar year and their company milestones, visit here. The biotech retained complete control in the Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Thoughts on the President’s State of the Union

Jim Greenwood

I had several thoughts watching President Obama’s State of the Union Address tonight. First, we at BIO remain concerned about the possible impact that sequestration may have – specifically the potential impact it may have on human health. There are millions of patients – all hopeful that new treatments will become available soon. Our fear is that sequestration may impact the ability of those patients to access new treatments in a timely manner. That fear Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , ,

How to Survive the Patent Cliff: Eli Lilly’s CEO at the BIO CEO & Investor Conference

Fireside Chat

Like a number of companies, Eli Lilly is confronting a wave of patent expirations called the patent cliff. The company lost U.S. patent protection on the anti-psychotic Zyprexa in the fall of 2011 and they’re facing the losses of the antidepressant Cymbalta in December of 2013 and the osteoporosis drug Evista in 2014. The loss of protection endangers the company’s ability to profit from the drugs and they could face a $25 billion loss in Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Word on the Street – Biotech Stocks Only Have Room to Go Up

The Opening Lunch Plenary at this year’s BIO CEO & Investor Conference was a lively discussion between portfolio managers and senior buy-side analysts looking to forecast the year ahead in biotech. BIO’s own, Celia Economides, Director, Investor Relations & Programs, reminded us all where we were 15 years ago at the inception of this event. At the 1999 event, there were 18 presenting companies, zero 1X1 meetings scheduled and 271 attendees.  As of day one, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,